How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,250 results for

Meningococcal Meningitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Characterization of strains of Neisseria meningitidis causing meningococcal meningitis in Mozambique, 2014: Implications for vaccination against meningococcal meningitis. (PubMed)

Characterization of strains of Neisseria meningitidis causing meningococcal meningitis in Mozambique, 2014: Implications for vaccination against meningococcal meningitis. In sub Saharan Africa, the epidemiology, including the distribution of serogroups of strains of N. meningitidis is poorly investigated in countries outside "the meningitis belt". This study was conducted with the aim to determine the distribution of serogroups of strains of N. meningitidis causing meningococcal meningitis (...) associated to serogroup B.Our data shows that the number of cases of meningococcal meningitis routinely reported in central hospitals in Mozambique is significant and the most dominant serogroup is A. In conclusion, although serogroup A has almost been eliminated from the "meningitis belt", this serogroup remains a major concern in countries outside the belt such as Mozambique.

Full Text available with Trip Pro

2018 PLoS ONE

2. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial (PubMed)

Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial Antibiotic prophylaxis for contacts of meningitis cases is not recommended during outbreaks in the African meningitis belt. We assessed the effectiveness of single-dose oral ciprofloxacin administered to household contacts and in village-wide distributions on the overall attack rate (AR) in an outbreak of meningococcal (...) meningitis.In this 3-arm, open-label, cluster-randomized trial during a meningococcal meningitis outbreak in Madarounfa District, Niger, villages notifying a suspected case were randomly assigned (1:1:1) to standard care (the control arm), single-dose oral ciprofloxacin for household contacts within 24 hours of case notification, or village-wide distribution of ciprofloxacin within 72 hours of first case notification. The primary outcome was the overall AR of suspected meningitis after inclusion. A random

Full Text available with Trip Pro

2018 EvidenceUpdates

3. Meningococcal Meningitis and Sepsis Guidance Note Diagnosis and Treatment in General Practice

Meningococcal Meningitis and Sepsis Guidance Note Diagnosis and Treatment in General Practice 1 Endorsed by the BMA Updated in line with NICE Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management CG102, NICE Sepsis: recognition, diagnosis and early management NG51, and NICE Fever in under 5s: assessment and initial management CG160. Meningococcal Meningitis and Sepsis Guidance Notes Diagnosis and Treatment in General Practice 2018 edition UK2 (...) the tumbler firmly against the skin to see if the rash blanches/fades *MRF are transitioning from the term ‘septicaemia’ to ‘sepsis’ in line with clinical practice3 Disease Pathway Meningococcal disease has two main clinical presentations: meningitis and sepsis, which often occur together. Sepsis is more common and more dangerous. It is most likely to be fatal when it occurs without meningitis 9 . A patient with sepsis can present with very different symptoms from someone with meningitis. This diagram

2018 Meningitis Research Foundation

4. Early management of suspected bacterial meningitis and meningococcal sepsis in immunocompetent adults

Early management of suspected bacterial meningitis and meningococcal sepsis in immunocompetent adults Suspected Meningitis (meningitis without signs of shock, severe sepsis or signs suggesting brain shift) Blood cultures Lumbar puncture Dexamethasone 10mg IV Ceftriaxone OR Cefotaxime 2g IV immediately following LP * (see also alternative initial antibiotics) CT scan normally not indicated Careful fluid resuscitation (avoid fluid overload) * If LP cannot be done in the first hour (...) Meningococcal Disease is excluded or Ceftriaxone has been given for 24 hours (or a single dose of Ciprofloxacin) Notify microbiology Public Health Notify all cases to the relevant public health authority for contact tracing, give antimicrobial prophylaxis and vaccination where necessary Early Management of Suspected Meningitis and Meningococcal Sepsis in Immunocompetent Adults Suspected meningitis with signs suggestive of shift of brain compartments secondary to raised intracranial pressure Get Critical

2016 Meningitis Research Foundation

5. Meningitis - bacterial meningitis and meningococcal disease

Meningitis - bacterial meningitis and meningococcal disease Meningitis - bacterial meningitis and meningococcal disease - NICE CKS Clinical Knowledge Summaries Share Meningitis - bacterial meningitis and meningococcal disease: Summary Bacterial meningitis is a life-threatening condition that can affect all ages, but is most common in babies and children. Transmission occurs through close contact, droplets, or direct contact with respiratory secretions. The annual incidence of acute bacterial (...) : stiff neck, altered mental state (confusion, delirium and drowsiness, impaired consciousness), non-blanching rash, back rigidity, bulging fontanelle (in children younger than 2 years of age), photophobia, Kernig's sign, Brudzinski's sign, coma, paresis, focal neurological deficit, and seizures. All suspected cases of meningitis are medical emergencies requiring immediate hospital admission by telephoning 999. For suspected meningococcal disease (meningitis with non-blanching rash or meningococcal

2016 NICE Clinical Knowledge Summaries

6. A case of a FilmArray<sup>®</sup> ME false negative in meningococcal meningitis. (PubMed)

A case of a FilmArray® ME false negative in meningococcal meningitis. The FilmArray® meningitis/encephalitis panel detects the 14 most frequent pathogens causing meningitis and/or encephalitis. The cases of FilmArray´s false negative in bacterial meningitis are rarely described in the literature. We are reporting a case of a false negative FilmArray® result for N. meningitidis and how we managed to overcome this situation.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 Journal of Infection

7. Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018

Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Ciprofloxacin (...) for the Prevention of Meningococcal Meningitis 2018 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03431675 Recruitment Status : Not yet recruiting First Posted : February 13, 2018 Last Update Posted : February 8, 2019 See Sponsor

2018 Clinical Trials

8. Cerebral Venous Sinus Thrombosis in a Patient with Meningococcal Meningitis (PubMed)

Cerebral Venous Sinus Thrombosis in a Patient with Meningococcal Meningitis Meningococcal meningitis has a wide range of neurological complications. However, cerebral venous sinus thrombosis (CVST) following infection with Neisseria meningitidis is uncommon. We report a case of CVST in a 42-year-old male admitted with meningococcal meningitis. The patient was managed with antibiotics. Due to altered coagulation parameters observed in fulminant cases of meningococcemia, deployment

Full Text available with Trip Pro

2018 Oman medical journal

9. Invasive meningococcal disease without meningitis: a forgotten diagnosis (PubMed)

Invasive meningococcal disease without meningitis: a forgotten diagnosis Neisseria meningitidis, a Gram-negative diplococcus, is an uncommon cause of pneumonia. There have been only about 344 cases reported worldwide from 1906 to 2015. To our knowledge, there have been only 3 cases reported in the USA in the past 2 decades. We present a case of a 72-year-old male with a past medical history of severe COPD, obstructive sleep apnea, and stage I lung cancer status post-stereotactic body radiation (...) meningococcal pneumonia requires a high level of suspicion, as sputum cultures may be falsely positive due to asymptomatic carriage of the organism in the upper respiratory tract in up to 10% of outpatient population. We highlight this case as early recognition and treatment is critical. The case fatality rate for N. meningitidis pneumonia has been reported to be higher compared with meningococcal meningitis.

Full Text available with Trip Pro

2018 International medical case reports journal

10. WITHDRAWN: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. (PubMed)

WITHDRAWN: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. Meningococcal polysaccharide (MPLS) vaccines protect against Serogroup C disease, but do not produce an immune response in infants less than two years of age. This limitation can be overcome by linking C polysaccharide to carrier proteins ('conjugating'), to create meningococcal serogroup C conjugate (MCC) vaccines. In the absence of trial data, the immune response to vaccination has been considered (...) to be a reasonable surrogate for vaccine protection.To assess the immunogenicity, safety and efficacy of MCC vaccines for preventing meningitis and septicaemia.We searched the Cochrane Central Register Controlled Trials (CENTRAL) (The Cochrane Library 2005, issue 3); MEDLINE (1966 to September, Week 1 2005); and EMBASE (1990 to June 2005) and references of studies.Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) in humans comparing MCC vaccines against a control vaccine or none

2011 Cochrane

11. HiberGene Meningococcal LAMP assay for rapid detection of meningitis and/or septicaemia

HiberGene Meningococcal LAMP assay for rapid detection of meningitis and/or septicaemia HiberGene Meningococcal LAMP assay for rapid detection of meningitis and/or septicaemia HiberGene Meningococcal LAMP assay for rapid detection of meningitis and/or septicaemia NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. HiberGene (...) Meningococcal LAMP assay for rapid detection of meningitis and/or septicaemia. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Enterovirus Infections; Humans; Immunoassay; Meningitis, Viral; Rhabdoviridae Infections Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre

2013 Health Technology Assessment (HTA) Database.

12. Meningococcal carriage within households in the african meningitis belt: a longitudinal pilot study. (PubMed)

Meningococcal carriage within households in the african meningitis belt: a longitudinal pilot study. Carriers of Neisseria meningitidis are a key source of transmission. In the African meningitis belt, where risk of meningococcal disease is highest, a greater understanding of meningococcal carriage dynamics is needed.We randomly selected an age-stratified sample of 400 residents from 116 households in Bamako, Mali, and collected pharyngeal swabs in May 2010. A month later, we enrolled all 202 (...) were identified from 1422 swabs analyzed, and 16.3% of individuals (33/202) were identified as carriers at least once. The majority of isolates were non-groupable; no serogroup A carriers were identified.Our results suggest that the duration of carriage with any N. meningitidis averages 2.9 months and that males and children acquire and lose carriage more frequently in an urban setting in Mali. Our study informed the design of a larger study implemented in seven countries of the African meningitis

Full Text available with Trip Pro

2017 Journal of Infection

13. Serogroup-Specific Characteristics of Localized Meningococcal Meningitis Epidemics in Niger 2002-2012 and 2015: Analysis of Health Center Level Surveillance Data. (PubMed)

Serogroup-Specific Characteristics of Localized Meningococcal Meningitis Epidemics in Niger 2002-2012 and 2015: Analysis of Health Center Level Surveillance Data.

Full Text available with Trip Pro

2016 PLoS ONE

14. Uncommon mixed outbreak of pneumococcal and meningococcal meningitis in Jirapa District, Upper West Region, Ghana, 2016 (PubMed)

Uncommon mixed outbreak of pneumococcal and meningococcal meningitis in Jirapa District, Upper West Region, Ghana, 2016 The Jirapa District in Ghana falls within the African meningitis belt where over 500 million people are at risk of epidemic meningitis. The district suffered an outbreak of Neisseria meningitides, W (NMW) in 2012 and a mixed outbreak of Streptococcus pneumonia and NMW in early 2016. We investigated the outbreak to identify the source, causative agents, and magnitude and assess (...) experienced a mixed outbreak of streptococcal and meningococcal meningitis in early 2016, facilitated by migration. Active surveillance and mass vaccination with multivalent vaccines is required to protect the population.Ghana Field Epidemiology and Laboratory Training Programme (GFELTP).

Full Text available with Trip Pro

2017 Ghana Medical Journal

15. Combined effect of PCV10 and meningococcal C conjugate vaccination on meningitis mortality among children under five years of age in Brazil (PubMed)

Combined effect of PCV10 and meningococcal C conjugate vaccination on meningitis mortality among children under five years of age in Brazil The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in the Brazilian National Immunization Program in March 2010, scheduled at 2, 4, and 6 months, with a booster at 12-15 months of age. The meningococcal C conjugate vaccine (MCC) was introduced in November 2010, scheduled at 3 and 5 months, with a booster dose at 12-15 months of age (...) and no catch-up for older age groups. In this interrupted time-series analysis study, we used Brazilian mortality data from 2005 to 2015 for children under five years of age (excluding data from the state of Bahia) to assess the combined impact of these vaccines on the overall burden of meningitis mortality among children aged 0-23 months and 2-4 years, as defined using meningitis and meningococcemia specific International Classification of Diseases - tenth revision codes. Secular trends and seasonality

Full Text available with Trip Pro

2017 Human vaccines & immunotherapeutics

16. Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa (PubMed)

Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa For more than a century, meningitis epidemics have regularly recurred across sub-Saharan Africa, involving 19 contiguous countries that constitute a 'meningitis belt' where historically the causative agent has been serogroup A meningococcus. Attempts to control epidemic meningococcal meningitis in Africa by vaccination with meningococcal polysaccharide (PS) vaccines have not been successful. This is largely because (...) PS vaccines are poorly immunogenic in young children, do not induce immunological memory, and have little or no effect on the pharyngeal carriage. Meningococcal PS-protein conjugate vaccines overcome these deficiencies. Conjugate meningococcal vaccine against serotype A (MenAfriVac) was developed between 2001 and 2009 and deployed in 2010. So far, 262 million individuals have been immunized across the meningitis belt. The public health benefits of MenAfriVac have already been demonstrated

Full Text available with Trip Pro

2017 Pathogens and global health

17. Effects of meteorological factors on the incidence of meningococcal meningitis (PubMed)

Effects of meteorological factors on the incidence of meningococcal meningitis Substantial climate changes have led to the emergence and re-emergence of various infectious diseases worldwide, presenting an imperative need to explore the effects of meteorological factors on serious contagious disease incidences such as that of meningococcal meningitis (MCM).The incidences of MCM and meteorology data between 1981 and 2010 were obtained from Chaoyang city. Structure Equation Modeling was used

Full Text available with Trip Pro

2017 African health sciences

18. Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial (PubMed)

Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial Epidemics of meningococcal meningitis are common in the "African meningitis belt." Current response strategies include reactive vaccination campaigns, which are often organized too late to have maximal impact. A novel strain of Neisseria meningitidis serogroup C has been circulating in recent years, and vaccine supplies are limited. An evaluation (...) of chemoprophylaxis with single-dose ciprofloxacin for household contacts of meningitis cases has therefore been recommended.A three-arm cluster-randomized trial has been designed for implementation during a meningococcal meningitis epidemic in a health district in Niger in which at least two Health Zones (HZs) have met the weekly epidemic threshold. The primary outcome is the incidence (attack rate) of meningitis during the epidemic. Villages will be randomized in a 1:1:1 ratio to one of three different arms

Full Text available with Trip Pro

2017 Trials

19. Meningococcal disease: guidance on public health management

of the vaccination status of the risk group ? for a cluster involving confirmed serogroup B cases: MenB vaccine should usually be offered to all individuals of any age who were offered antibiotics and who have not received the vaccine in the previous 12 months Guidance for Public Health Management of Meningococcal Disease in the UK: Updated February 2018 6 1. Background Neisseria meningitidis is a major cause of septicaemia and meningitis worldwide and is associated with significant mortality as well as serious (...) media access to vaccination sites, and regular coordinated press briefings and to hold press conferences (82) . Guidance for Public Health Management of Meningococcal Disease in the UK: Updated February 2018 46 Box Three: Helplines and leaflets Meningitis charities and NHS111/NHS 24/NHS Direct The meningitis charities may be contacted when there is a case of meningococcal disease. They need to have sufficient information so that they can support callers with appropriate advice. The information given

2019 Public Health England

20. Meningococcal disease

Meningococcal disease Meningococcal disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Meningococcal disease Last reviewed: February 2019 Last updated: November 2018 Summary Acute contagious illness, characterised by fever, petechial or purpuric rash, and signs of sepsis and/or meningitis. May progress rapidly to septic shock, with hypotension, acidosis, and disseminated intravascular coagulation. Highest rates (...) of invasive infection are in children under 5 years of age, especially under 1 year of age, with a second peak occurring in 11- to 22-year-olds and third peak in people >65 years of age. Diagnosis confirmed by isolation of Neisseria meningitidis from a normally sterile body site. Confirmed meningococcal infection is treated with a third-generation cephalosporin. Where a cephalosporin is not appropriate, the choice of agent is based on the individual patient circumstances, antibiotic susceptibilities

2018 BMJ Best Practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>